Sunday 15 July 2018
Contact US    |    Archive
Reuters
22 days ago

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 (Reuters) - Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo s Ozempic or Eli Lilly s dulaglutide, marketed as Tr

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

Novo

 | 

reveals

 | 

more

 | 

Ozempic

 | 

data

 | 

change

 | 

body

 | 

weight

 | 

baseline

 | 

BMI

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
USA